| 1.96 -0.19 (-8.84%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.66  |
1-year : | 2.92 |
| Resists | First : | 2.28 |
Second : | 2.5 |
| Pivot price | 2.18 |
|||
| Supports | First : | 1.93 |
Second : | 1.61 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 2.21 |
| MA(100) : | 1.82  |
MA(250) : | 2.05 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 16 |
D(3) : | 19.2 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 3.45 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ERNA ] has closed below the lower bollinger band by 20.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.22 | 2.22 - 2.23 |
| Low: | 1.9 - 1.92 | 1.92 - 1.93 |
| Close: | 1.94 - 1.96 | 1.96 - 1.98 |
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Fri, 15 Mar 2024
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 - InvestorPlace
Sun, 03 Mar 2024
ERNA Stock Quote Price and Forecast - CNN
Tue, 20 Feb 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - Yahoo Finance
Wed, 20 Dec 2023
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Yahoo Finance
Thu, 14 Dec 2023
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewswire
Wed, 06 Sep 2023
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.95e+006 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.059e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | 911.7 % |
| Return on Equity (ttm) | -36.2 % |
| Qtrly Rev. Growth | 68000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -37.04 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 39 |
| Dividend | 0 |
| Forward Dividend | 42430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|